In this recent article from Managed Healthcare, I highlighted the potential savings of #biosimilars and encouraged policymakers to take steps to foster greater biosimilar adoption. Read more here ⬇️ managedhealthcareexecutive.com/view/u-s-saved…

September was an exciting month for the Biosimilars Council as we announced the topline findings of our 2021 Generic Drug and Biosimilars Savings in the U.S. Report. Read our September Biosimilars Bulletin here: biosimilarscouncil.org/resource/biosi…

The #GRxBiosims 2021 virtual conference is November 8-10! Join AAM & the Biosimilars Council for invaluable information & insights on generics and biosimilars from industry experts and government officials like Dr. Janet Woodcock. Register here ➡️ grxbiosims.org

“The promise of #biosimilars is coming into view, but it won’t be fully realized until more policymakers & physicians understand the value proposition of these FDA-approved treatments.” — Christine Simmon Biosimilars Council View report: accessiblemeds.org/resources/repo… #GRxBiosimsSavingsReport

Congress is considering inflation-based rebate penalties in #Medicare to address high brand-name drug costs. AAM SVP Erik Komendant shares why this proposal could hurt competition & threaten #patientaccess to affordable #generic & #biosimilar medicines. accessiblemeds.org/resources/blog…

We are just one week away from #GRxBiosims 2021, and I invite you to join AAM & the Biosimilars Council virtually Nov. 8-10 to meet the leaders and decision-makers who are determining the future of generics and #biosimilars. Register here ➡️ grxbiosims.org

#GRxBiosims 2021 is next week (Nov. 8-10), and I invite you to join AAM & the Biosimilars Council for three days packed with invaluable insights and information on #biosimilars & #generics from industry experts. Register here ➡️ grxbiosims.org

The negotiation framework in #BuildBackBetter undermines tremendous savings generated by the #biosimilars industry and constrains patient access in the process. The evidence is clear. Read our latest blog post from the Biosimilars Council to learn more: bit.ly/3EsZbrG

Between participating in Global Biosimilars Week and hosting the GRx+Biosims 2021 conference, November was a busy month for the Biosimilars Council. Read our November #Biosimilars Bulletin to learn more ➡️ biosimilarscouncil.org/resource/biosi…

At AAM & Biosimilars Council, we're looking forward to #Access2022, our preeminent conference taking place on Feb. 14-16. I hope to see you all there in person in Orlando, FL to discuss what the future holds for the #biosimilars industry: youtube.com/watch?v=yUNCl6…

Next week at #Access2022 I will be joined by Steven Allison (Steven Allison, PharmD), Martin Arès, Bret Jackson & Dr. Steve Miller to discuss the various stakeholders leveraging #biosimilar competition today. Don't miss out! Register here: access.accessiblemeds.org Biosimilars Council

The Biosimilars Council looks forward to continuing our mission to increase patient access to #biosimilars this year. Read our latest blog post to catch a glimpse into what's on our agenda in 2022: biosimilarscouncil.org/resource/incre…

Valentine, I love you ❤️ And you say you love me If Medicare Plans love #generics Why are most now on brand tiers in Part D?    Valentine, I need more of you And I know our future is bright.  Ditto for #biosimilars 💉 So let’s get the policies right. #HealthPolicyValentines

I said that I love you But got back only crickets Are you with the #biosimilars, Stuck in the patent thickets? #HealthPolicyValentines

Today at #Access2022, I will be joined by Martin Ares from Sandoz, Bret Jackson from EAM, Steven Allison from AdventHealth and Steve Miller from Cigna Healthcare for "Leveraging Biosimilar Competition for Success." You won't want to miss it!

It was great to speak backstage with Lachman Consultants's Frances Zipp, AMCP's Susan Cantrell (Susan A. Cantrell), and Sandoz's Keren Haruvi back stage at #Access2022! They shared great ideas about how to inspire the next generation of women in health care. #WiHP #Access2022

This is #MarkupMadness. Stop middlemen from adding to the cost of the generic prescription medicines millions of America’s patients rely on each day to manage their health! markupmadness.org

Today I will be joining The Public Sector HealthCare Roundtable for the webinar, "Biosimilars in the US: Benefits, Public Policies and Opportunities." Register to hear perspectives from the Biosimilars Council and Sandoz on the evolving #biosimilar policy landscape: bit.ly/3JBfoga

The Biosimilars Council's comment to the FTC today outlines harmful Pharmacy Benefit Manager practices: bit.ly/3LMvXqE #Biosimilars are lower cost options, but too often PBMs do not encourage their use.